{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-027933","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.455171+00:00","generated_at":"2026-06-12T02:39:04.197916+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Foghorn Therapeutics appoints Alfonso Quintás-Cardama as CMO; Sam Agresta departs Sept 11, 2023","bullets":["Samuel Agresta steps down as CMO effective September 11, 2023; will consult through early January 2024.","Alfonso Quintás-Cardama appointed CMO effective September 11, 2023; previously CMO at TCR2 Therapeutics.","Dr. Quintás-Cardama helped develop Kymriah (tisagenlecleucel) at Novartis and led cell therapy clinical dev at GSK.","He was a faculty member at MD Anderson Cancer Center (2009-2014) developing targeted agents for myeloid malignancies."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-027933","json":"https://secwatch.observer/filing/0001628280-23-027933.json","markdown":"https://secwatch.observer/filing/0001628280-23-027933.md","text":"https://secwatch.observer/filing/0001628280-23-027933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023027933/0001628280-23-027933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023027933/fhtx-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:39:04.197916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}